We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+5.76%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$199M
AUM Growth
+$11.2M
Cap. Flow
-$26K
Cap. Flow %
-0.01%
Top 10 Hldgs %
99.18%
Holding
18
New
7
Increased
2
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
TOVX icon
Theriva Biologics
TOVX
+$1.96M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$1.8M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$1.19M
4
INO icon
Inovio Pharmaceuticals
INO
+$851K
5
ADXS
Advaxis Inc
ADXS
+$849K

Top Sells

Rank Stock Value
1
VVUS
Vivus Inc
VVUS
+$4.83M
2
GNW icon
Genworth Financial
GNW
+$2.7M
3
CELG
Celgene Corp
CELG
+$225K
4
EXAS
Exact Sciences
EXAS
+$165K

Sector Composition

Rank Sector Weight
1 Healthcare 17.97%
2 Technology 0.46%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$159M 79.84%
4,968,202
– –
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$14.5M 7.28%
6,757
– –
ARCT icon
3
Arcturus Therapeutics
ARCT
$157M
$12.4M 6.23%
98,143
+14,286
+17% +$1.8M
KERX
4
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.59M 1.31%
200,000
+100,000
+100% +$1.19M
SQNM
5
DELISTED
SEQUENOM INC NEW
SQNM
$2.07M 1.04%
893,600
– –
TOVX icon
6
Theriva Biologics
TOVX
$10.2M
$2.05M 1.03%
+155
New +$1.96M
LUMO
7
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.7M 0.86%
8,604
– –
INO icon
8
Inovio Pharmaceuticals
INO
$79.8M
$1.17M 0.59%
+8,507
New +$851K
VVUS
9
CALL
DELISTED
Vivus Inc
VVUS
$1.05M 0.53%
+500
New +$48.3K
ADXS
10
DELISTED
Advaxis Inc
ADXS
$947K 0.48%
+15,000
New +$849K
PRKR
11
DELISTED
Parkervision Inc
PRKR
$910K 0.46%
+20,000
New +$772K
MACK
12
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$400K 0.2%
+9,533
New +$276K
ADXSW
13
DELISTED
Advaxis Inc Warrants
ADXSW
$186K 0.09%
+112,500
New +$151K
ECTE
14
DELISTED
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
$140K 0.07%
44,445
– –
EXAS
15
DELISTED
Exact Sciences
EXAS
– –
-14,000
Closed -$165K
GNW icon
16
Genworth Financial
GNW
$3.8B
– –
-211,000
Closed -$2.7M
VVUS
17
DELISTED
Vivus Inc
VVUS
– –
-50,000
Closed -$4.83M
CELG
18
DELISTED
Celgene Corp
CELG
– –
-55,850
Closed -$225K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, Knoll Capital Management held 18 positions worth $199M, up 6% from $187M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Knoll Capital Management's Q4 2013 filing shows 7 new, 2 increased and 4 closed positions. Its largest new stake was Theriva Biologics: 155 shares worth $2.05M. The largest sale was Vivus Inc, an estimated $4.83M.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Financials.

  • Knoll Capital Management's largest Q4 2013 buy was Theriva Biologics: 155 shares worth $2.05M.
  • Knoll Capital Management added most to Arcturus Therapeutics in Q4 2013, an estimated $1.8M increase.
  • Knoll Capital Management fully exited Vivus Inc in Q4 2013, selling an estimated $4.83M.
  • Knoll Capital Management's ten largest holdings make up 99% of its $199M portfolio in Q4 2013.
  • Knoll Capital Management opened 7 new positions and closed 4 in Q4 2013.
  • Knoll Capital Management's portfolio value rose 6% quarter-over-quarter to $199M.

Based on Knoll Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.